Our present study also examined the regulatory effects of CCL2 on different breast cancer cells, while disrupting CCL2-CCR2 axis by CCR2 antagonist RS102895 could attenuate these effects partially due to downregulation of MMP-9 and VEGF expression in vitro. Here, VEGFA is linked to breast carcinoma.